Jonas Bergh is a professor of Oncology at Karolinska Institutet (KI) and a senior consultant at Karolinska University Hospital in Stockholm, Sweden. He is a member of the Nobel Assembly and director of the Strategic Research Program in Cancer at KI.  

Professor Bergh was Chair of the Swedish Breast Cancer Group between 1995 and 2016. During this period he conducted clinical trials with new drugs and individually tailored dosing of chemotherapy. Through this group, he also participated in the first randomised study showing that five years of tamoxifen treatment is better that the previously recommended two years. He has been involved in showing the additional value of other drugs, in particular chemotherapy, in breast cancer treatment.  Professor Bergh has an extensive scientific publication record of > 400 publications. Professor Bergh was the acting Chair of the Scientific Advisory Group Oncology-Hematology at the European Medicines Agency (EMA), where he was a member since 2004. He has been co-chairman for a global network, Early Breast Cancer Trialists’ Collaborative Group, with over 600 clinical scientists. The group’s publications have a globally great impact on primary breast cancer treatment. Professor Bergh is a member of the consensus panels establishing treatment recommendations for primary and metastatic breast cancer. He is also a fellow at the Royal College of Physicians in London, a member of the scientific council IARC for WHO and visiting Professor of Breast Cancer Research, at Oxford University.